Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Jounce Therapeutics Inc (JNCE)

Jounce Therapeutics Inc (JNCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Jounce Therapeutics Inc 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 USA

www.jouncetx.com P: 857-259-3840 F: 888-459-2940

Description:

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.

Key Statistics

Overview:

Market Capitalization, $K 98,954
Enterprise Value, $K -90,586
Shares Outstanding, K 52,635
Annual Sales, $ 82,000 K
Annual Net Income, $ -50,920 K
Last Quarter Sales, $ 82,000 K
Last Quarter Net Income, $ 50,960 K
60-Month Beta 0.75
% of Insider Shareholders 6.92%
% of Institutional Shareholders 80.66%
Float, K 48,993
% Float 93.08%
Short Volume Ratio 0.40

Growth:

1-Year Return -63.21%
3-Year Return -60.34%
5-Year Return -88.80%
5-Year Revenue Growth 14.46%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.60 on 11/10/22
Latest Earnings Date 05/04/23
Earnings Per Share ttm -1.97
EPS Growth vs. Prev Qtr 7.69%
EPS Growth vs. Prev Year -1.69%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

JNCE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -30.90%
Return-on-Assets % -26.31%
Profit Margin % -62.10%
Debt/Equity 0.00
Price/Sales 1.24
Price/Cash Flow N/A
Price/Book 0.53
Book Value/Share 3.54
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar